Dr. Silberman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
508 Fulton St
Durham, NC 27705Phone+1 828-257-2333
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1988 - 1992
NYU Grossman School of MedicineResidency, Internal Medicine, 1985 - 1987
Weill Cornell MedicineClass of 1985
Certifications & Licensure
NC State Medical License 2016 - 2023
NJ State Medical License 2002 - 2017
CT State Medical License 1992 - 2005- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients Start of enrollment: 2004 Feb 01
- Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies Start of enrollment: 2005 Nov 01
- A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer Start of enrollment: 2007 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 1689 citationsKinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorMichael Heinrich, Christopher L. Corless, George D. Demetri, Charles D. Blanke, Margaret von Mehren
Journal of Clinical Oncology. 2003-12-01 - 929 citationsSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.Allan T. van Oosterom, Ian Judson, Jaap Verweij, Sigrid Stroobants, Eugenio Donato di Paola
Lancet. 2001-10-27 - 425 citationsManagement of malignant gastrointestinal stromal tumours.Heikki Joensuu, Christopher D.M. Fletcher, Sasa Dimitrijevic, Sandra Silberman, Peter J. Roberts
The Lancet. Oncology. 2002-11-01
Press Mentions
Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of CancerMarch 9th, 2023- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with BerubicinDecember 12th, 2022
- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM TreatmentAugust 2nd, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
